ELTX Elicio Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: ELTX

Price (delayed)

$8.98

Market cap

$91.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.96

Enterprise value

$85.22M

Highlights
Elicio Therapeutics's EPS has soared by 92% YoY and by 73% from the previous quarter
ELTX's debt is down by 8% YoY and by 3.3% QoQ
ELTX's equity has surged by 111% year-on-year but it is down by 14% since the previous quarter
The quick ratio has increased by 22% YoY but it has decreased by 3.5% QoQ
The net income has declined by 25% year-on-year and by 20% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of ELTX
Market
Shares outstanding
10.24M
Market cap
$91.91M
Enterprise value
$85.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$34.14M
EBITDA
-$32.97M
Free cash flow
-$32.73M
Per share
EPS
-$6.96
Free cash flow per share
-$6.47
Book value per share
$1.35
Revenue per share
$0
TBVPS
$5.37
Balance sheet
Total assets
$27.15M
Total liabilities
$15.77M
Debt
$6.92M
Equity
$11.37M
Working capital
$6.58M
Liquidity
Debt to equity
0.61
Current ratio
1.67
Quick ratio
1.39
Net debt/EBITDA
0.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-102.4%
Return on equity
-160.2%
Return on invested capital
-288.2%
Return on capital employed
-196.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELTX stock price

How has the Elicio Therapeutics stock price performed over time
Intraday
-0.22%
1 week
-0.11%
1 month
21.85%
1 year
-86.75%
YTD
7.67%
QTD
18.16%

Financial performance

How have Elicio Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$35.75M
Net income
-$35.2M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 51% year-on-year and by 23% since the previous quarter
The net income has declined by 25% year-on-year and by 20% since the previous quarter

Growth

What is Elicio Therapeutics's growth rate over time

Valuation

What is Elicio Therapeutics stock price valuation
P/E
N/A
P/B
6.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Elicio Therapeutics's EPS has soared by 92% YoY and by 73% from the previous quarter
ELTX's equity has surged by 111% year-on-year but it is down by 14% since the previous quarter
The price to book (P/B) is 101% higher than the last 4 quarters average of 3.3

Efficiency

How efficient is Elicio Therapeutics business performance
The company's return on assets has shrunk by 114% YoY and by 16% QoQ
ELTX's return on invested capital is down by 31% since the previous quarter but it is up by 31% year-on-year
The ROE has contracted by 7% YoY

Dividends

What is ELTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELTX.

Financial health

How did Elicio Therapeutics financials performed over time
The total assets is 72% greater than the total liabilities
The quick ratio has increased by 22% YoY but it has decreased by 3.5% QoQ
The total assets is up by 20% year-on-year but it has declined by 12% since the previous quarter
ELTX's debt is 39% lower than its equity
ELTX's equity has surged by 111% year-on-year but it is down by 14% since the previous quarter
Elicio Therapeutics's debt to equity has increased by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.